Tigo Energy to Recognize Residential Installers with Loyalty Program at Intersolar Europe 2024
10.6.2024 16:00:00 EEST | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced it will unveil the new Tigo Installer Loyalty Program for residential PV installers in EMEA at Intersolar Europe 2024. As sustainable energy sources comprised 30% of all energy generated globally in 2023, with solar becoming an increasingly large contributor to that output, Tigo Energy is committed to supporting and invigorating the solar industry through initiatives like this loyalty program. Through exclusive benefits and solutions, the Tigo Installer Loyalty Program will recognize the dedication and professionalism of installers who choose Tigo solutions, further supporting their continued success and emphasizing the vitality of all members of the solar value chain to ensure the health of the solar industry.
Intersolar Europe 2024 attendees are invited to learn more about the training requirements and other qualifications for the Tigo Installer Loyalty Program by attending one of the scheduled program overview presentations. A comprehensive calendar of these introductory sessions is available on this page. Tigo will also offer the opportunity to enroll in the program at the event.
“We have worked with Tigo for years, and we are delighted to see this initiative come to installers here in the EMEA region,” said Michael Schmittinger, Managing Director at MMS Communication GmbH & Co. KG. “Our technicians and system designers have gained much from the Tigo Academy training resources, so I am happy to see this platform continue to be a focus in the loyalty program. We look forward to getting involved, learning, contributing, and continuing to build our solar business.”
“As the solar industry converges on Intersolar Europe in Munich, we are excited to welcome PV professionals into our new Installer Loyalty Program, introduce our latest MLPE products, and showcase the power of Tigo software to enhance system performance,” said Mirko Bindi, Senior VP Sales EMEA & MD Europe at Tigo Energy. “At Tigo, we are building the technology and service-oriented culture to empower all solar installers to embrace continuous improvement and a dedication to quality across the entire solar value chain. Underpinning these initiatives is a constantly evolving set of software capabilities that are quickly becoming the catalyst to achieving these goals, and we are very excited to showcase all of this at Intersolar Europe this year.”
With three tiers of participation, the Tigo Installer Loyalty Program offers progressively more valuable benefits for participants, including co-branding, homeowner sales leads, customized collateral, and promotion via the Tigo newsletter. Program participants will also be able to gain early access to new product developments, including participation in Tigo installer council sessions to provide the Company feedback. In addition to the new loyalty program, Tigo will showcase the Tigo EI Residential Solution, now extended to e-mobility with the GO EV Charger. The Company will also showcase the recently-released TS4-X, a new family of Flex MLPE solutions for high-power solar modules, providing safety, monitoring, optimization, and a new Multi-Factor Rapid Shutdown (MFRS) capability for energy-critical applications. Remaining true to the Company’s commitment to open architectures and broad compatibility, products within the TS4-X family work with the largest selection of third-party inverters, supporting the latest high-power and bifacial solar modules, up to 800W.
“We have carried Tigo products in our portfolio for more than ten years, and the new high-power TS4-X optimizers are an outstanding addition to our product range,” said Justin Gann, marketing manager for products and suppliers at Krannich Group GmbH. “We will exhibit the entire range of Tigo solutions at Intersolar this year because these products have proven to be very reliable and of high quality, and they are becoming increasingly popular with our customers. We are delighted to have a high-quality professional provider like Tigo in our portfolio.”
Additionally, Tigo will hold two Technical Coffee Breaks, during which solar professionals can review the specifications of the new TS4-X product family and the EI Residential Solution with members of the Tigo product team. Participation in the Technical Coffee Breaks is free, and the sessions will be held on June 19th and 20th at 16:00 at the Tigo booth (#B4.239).
Please visit the scheduling page here to view a complete list of partners displaying Tigo solutions, register for an Installer Loyalty Program presentation, or schedule a meeting with a member of the Tigo team. To inquire about the Installer Loyalty Program, visit here.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610982934/en/
Contact information
Technica Communications
Cait Caviness
Email: tigoenergy@technica.inc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom